Tag

Drugs – statins

#129 – Tom Dayspring, M.D.: The latest insights into cardiovascular disease and lipidology

Atherogenic lipoproteins are really the issue behind clinical atherosclerotic vascular disease. … The data has just become so overwhelming.” —Tom Dayspring

#116 – AMA with Dom D’Agostino, Ph.D., Part I of II: Ketogenic diet, exogenous ketones, and exercise

“If you restore insulin sensitivity, you’re better able to access and burn fat.” — Dom D’Agostino

#23 – Tom Dayspring, M.D., FACP, FNLA – Part IV of V: statins, ezetimibe, PCSK9 inhibitors, niacin, cholesterol and the brain

“This is what it ultimately comes down to – and it’s the way you practice – you’ve got to individualize everything.” –Tom Dayspring

Narrative glossary: lipids

A companion post for the podcast episodes with Thomas Dayspring, M.D., FACP, FNLA (October 15-19, 2018).

Statins, Lp(a), and upcoming podcast guests

In other words, statins are not addressing the associated risk in patients with an elevated Lp(a), and this population represents about 25% of those with previous CVD or an indication for statins.

#18 – Richard Isaacson, M.D.: Alzheimer’s prevention

“Anyone with a brain is at risk for Alzheimer’s.” —Richard Isaacson

#03 – Ron Krauss, M.D.: a deep dive into heart disease

“Anybody interested in this field should probably understand the origins.” —Ron Krauss

Facebook icon Twitter icon Instagram icon Pinterest icon Google+ icon YouTube icon LinkedIn icon Contact icon